Galimberti, S.; Abruzzese, E.; Luci, G.; Baratè, C.; Luciano, L.; Iurlo, A.; Caocci, G.; Morganti, R.; Stefanelli, F.; Di Paolo, A.
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia. Pharmaceutics 2024, 16, 383.
https://doi.org/10.3390/pharmaceutics16030383
AMA Style
Galimberti S, Abruzzese E, Luci G, Baratè C, Luciano L, Iurlo A, Caocci G, Morganti R, Stefanelli F, Di Paolo A.
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia. Pharmaceutics. 2024; 16(3):383.
https://doi.org/10.3390/pharmaceutics16030383
Chicago/Turabian Style
Galimberti, Sara, Elisabetta Abruzzese, Giacomo Luci, Claudia Baratè, Luigia Luciano, Alessandra Iurlo, Giovanni Caocci, Riccardo Morganti, Fabio Stefanelli, and Antonello Di Paolo.
2024. "A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia" Pharmaceutics 16, no. 3: 383.
https://doi.org/10.3390/pharmaceutics16030383
APA Style
Galimberti, S., Abruzzese, E., Luci, G., Baratè, C., Luciano, L., Iurlo, A., Caocci, G., Morganti, R., Stefanelli, F., & Di Paolo, A.
(2024). A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia. Pharmaceutics, 16(3), 383.
https://doi.org/10.3390/pharmaceutics16030383
